New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

OSTEOPATHIC manipulative treatment (OMT) may improve pulmonary function in asthma, though current evidence remains limited ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

Dhaka ranked 10th among the world’s most polluted cities on Friday morning, recording an Air Quality Index (AQI) of 126 at 11 ...

For children with single-ventricle disease, death or major morbidity occurs in 87%, and shunt type impact varies.

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, ...

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...